SAFC Partners with CatScI Ltd to Offer Comprehensive Catalysis Services
Sigma-Aldrich Corporation has announced that SAFC Commercial, its custom manufacturing services business unit, has entered into a services agreement with CatScI Ltd, a UK-based catalysis company focused on maximising yield, optimising quality, reducing waste and minimising chemical development costs through reaction understanding.
SAFC customers will immediately benefit from the relationship through rapid access to new reactions, homogeneous and heterogeneous catalysis, biocatalysts, solvent selection and process development, in addition to metal removal, recovery and recycling services.
“The strategic partnership combines CatScI’s extensive expertise in catalysed reactions and complex chemical processes with SAFC’s strength in process development, scale-up and manufacturing of high-value products,” said Andreas Weiler, Head of Global Strategic Marketing for Contract Manufacturing Services & Solutions at SAFC. “As a combined offering, we are able to provide customers a single source for high-quality, high-value fundamental research, development, scale-up and manufacture, with additional process development resources for customers to screen projects more quickly, and efficiently maximise catalyst reactions using the appropriate ligands, solvents and science.”
“The level of collaboration builds naturally on each company’s strong foundation. CatScI’s technology platform and methodology is differentiated to provide unique research and development in a cost- and time-efficient manner. Customers can take advantage of our expertise in both chemo- and bio-catalysis for the suggestion, screening, selection, development and optimisation of reactions and processes. In essence, we provide innovative solutions to all types of challenging synthetic chemistry problems,” said Simon Tyler, Commercial Director at CatScI Ltd.
The importance of catalysis to the pharmaceutical industry has steadily grown over the past two decades due to several interrelated factors: increasing regulatory requirements such as policies on single-enantiomer drugs and environmental protection; the pressure to reduce drug development cost and time; and the continued discovery of new practical catalysts from both academia and industry. Approximately 90% of chemicals now require the use of catalytic processes in their manufacture. With chemical targets becoming more complex and the average number of transformations required to synthesise an API continuing to climb and currently averaging 12 synthetic steps, industrial chemists look increasingly to employ catalysis to achieve concise and economical processes in R&D and production.
CatScI Ltd employs a combination of computational, statistical and synthetic methods and advanced technology for the rational exploration of reaction space, with access to hundreds of different catalysts and extensive experience in the investigation of the influence of the many experimental parameters at play.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance